key: cord-0292233-bre2ijbb
authors: TOGETHER Trial,; Reis, G.; Silva, E.; Silva, D.; Thabane, L.; Milagres, A.; Ferreira, T.; dos Santos, C.; Neto, A.; Callegari, E.; Savassi, L.; Campos, V.; Simplicio, M.; Ribeiro, L.; Oliveira, R.; Harari, O.; Forrest, J.; Hinda, R.; Sprague, S.; McKay, P.; Glushchenko, A.; Rayner, C.; Lenze, E.; Reierson, A.; Guyatt, G.; Mills, E.
title: EFFECT OF EARLY TREATMENT WITH FLUVOXAMINE ON RISK OF EMERGENCY CARE AND HOSPITALIZATION AMONG PATIENTS WITH COVID-19: THE TOGETHER RANDOMIZED PLATFORM CLINICAL TRIAL
date: 2021-08-23
journal: nan
DOI: 10.1101/2021.08.19.21262323
sha: 94a490f13ac08bcb5c3e5c546e10f4837366a62e
doc_id: 292233
cord_uid: bre2ijbb

Background Recent evidence indicates a potential therapeutic role of fluvoxamine for COVID-19. In the TOGETHER randomized platform clinical trial for acutely symptomatic patients with COVID-19, we assessed the efficacy of fluvoxamine vs. placebo in preventing either extended emergency room observation or hospitalization due to COVID-19. Herein, we report the preliminary findings. Methods This placebo-controlled, randomized, adaptive, platform trial conducted among symptomatic Brazilian adults confirmed positive for SARS-CoV-2 included eligible patients with a known risk factor for progression to severe disease. Patients were randomly assigned to either fluvoxamine (100 mg twice daily for 10 days) or placebo. The primary endpoint was a composite outcome of emergency room observation for >6 hours or hospitalization from COVID-19 up to 28 days post randomization. Secondary outcomes included viral clearance at day 7, time to hospitalization, mortality, and adverse drug reactions. We used a Bayesian analytic framework to determine effects along with probability of success of intervention compared to placebo. The trial is registered at clinicaltrials.gov (NCT04727424) and is ongoing. Results The study team screened 9020 potential participants for this trial. The trial was initiated on June 2, 2020, with the current protocol reporting randomization from January 15, 2021 to August 6th 2021, when the trial arms were stopped for superiority. A total of 3238 patients were allocated to fluvoxamine (n=739), placebo (n=733) and other treatments (n=1766). Herein, we report the effectiveness of fluvoxamine vs. a concurrent placebo control. The average age of participants was 50 years (range 18-102 years); 57% were female. The proportion of patients observed in an emergency room for >6 hours or admitted to hospital due to COVID-19 was lower for the fluvoxamine group compared to placebo (77/739 vs 108/733; Relative Risk [RR]: 0.71; 95% Bayesian Credible Interval [95% BCI]: 0.54 - 0.93), with a probability of superiority of 99.4% surpassing the prespecified superiority threshold of 97.6% (risk difference 4.3%). Of the composite primary outcome events, 88% were hospitalizations. We found no significant relative effects between the fluvoxamine and placebo groups on viral clearance at day 7 (Odds ratio [OR]: 0.75; 95% Confidence Intervals [95% CI]: 0.53 - 1.07), mortality (OR: 0.70; 95% CI: 0.36 - 1.30), time to death (Hazard ratio [HR]: 0.79; 95% CI: 0.58 - 1.08), days hospitalized (Mean Difference (MD) 1.22 days; 95% CI: 0.98 - 1.53), number of days ventilated (MD 1.10; 95% CI: 0.70 - 1.73) or other secondary outcomes. Data capturing all 28 days of follow-up will be reported after August 26th, 2021. Conclusions Treatment with fluvoxamine (100 mg twice daily for 10 days) among high-risk outpatients with early diagnosed COVID-19, reduced the need for extended emergency room observation or hospitalization. Funding The trial was supported by FastGrants and The Rainwater Foundation.

The TOGETHER Trial is a randomized adaptive platform trial to investigate the efficacy of 80 repurposed treatments for COVID-19 disease among high-risk adult outpatients. 9 The trial was 81 designed and conducted in partnership with local public health authorities from eleven 82 participating cities in Brazil to simultaneously test potential treatments for early disease using a 83 master protocol. A master protocol defines prospective decision criteria for discontinuing 84 interventions for futility, stopping due to superiority against placebo, or adding new interventions. 85

Interventions evaluated in the TOGETHER trial, thus far, include, hydroxychloroquine (protocol 86 1), lopinavir/ritonavir (protocol 1), 10 metformin, ivermectin, fluvoxamine, doxasozin and 87 pegylated interferon lambda versus matching placebos (protocol 2). 88

The trial began on June 2, 2020 and enrollment into the fluvoxamine arm began on January The steering committee made all protocol-related decisions and sponsors had no role in trial 96 conduct, data analysis or decision to submit manuscript for publication. An independent Data 97 Safety Monitoring Committee (DSMC) provided trial oversight. 98 99 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.19.21262323 doi: medRxiv preprint

The appended web-appendix lists the cities and investigators of the eleven clinical sites in Brazil 101 that participated in the trial. Local investigators, in partnership with local public health authorities, 102 recruited participants at community health facilities (emergency settings, flu-symptom referral 103 centers, primary care community centers). We used several community outreach strategies 104 including physical and social media as per local public health authorities, in order to create 105 awareness of the trial. 106

Upon presentation to one of the trial outpatient care clinics, local investigators screened potential 108 participants to identify those who met the eligibility criteria. 109

The key inclusion criteria were: 1) patients over the age of 18, 2) presenting to an outpatient 110 care setting with an acute clinical condition consistent with COVID-19 and symptoms beginning 111 within 7 days of the screening date, 3) positive rapid test for SARS-CoV-2 antigen performed at 112 the time of screening or patient with positive SARS-CoV-2 diagnostic test within 7 days of 113 symptom onset, 4) at least one additional criterion for high-risk: diabetes mellitus; systemic 114 arterial hypertension requiring at least one oral medication for treatment; known cardiovascular 115 diseases (heart failure, congenital heart disease, valve disease, coronary artery disease, 116 cardiomyopathies being treated, clinically manifested heart disease and with clinical repercussion); 117 symptomatic lung disease and / or being treated (emphysema, fibrosing diseases); symptomatic 118 asthma patients requiring chronic use of agents to control symptoms; smoking; obesity, defined as 119 BMI>30 kg / m 2 (weight and height information provided by the patient); transplant patients; 120 patient with stage IV chronic kidney disease or on dialysis; immunosuppressed patients / using 121 corticosteroid therapy (equivalent to at least 10 mg of prednisone per day) and / or 122 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.19.21262323 doi: medRxiv preprint immunosuppressive therapy; patients with a history of cancer in the last 0.5 years or undergoing 123 current cancer treatment, or age ³ 50 years; and unvaccinated status. 124

Patients who met any of the following criteria were excluded from the trial: 1) Diagnostic 125 examination for SARS-CoV2 negative associated with acute flu-like symptoms (patient with 126 negative test taken early and becoming positive a few days later were eligible, if he/she was <7 127 days after the onset of flu-like symptoms); 2) Acute respiratory condition compatible with COVID-128 19 treated in the primary care and previously requiring hospitalization; 3) Acute respiratory 129 condition due to other causes; 4) Received vaccination for SARS-CoV2; 5) Dyspnea secondary to 130 other acute and chronic respiratory causes or infections (e.g., decompensated COPD, acute 131 bronchitis, pneumonia, primary pulmonary arterial hypertension); 6) Current use of selective 132 serotonin reuptake inhibitors; uncontrolled psychiatric disorders; or suicidal ideation; 7) Inability 133 or unwillingness to follow research guidelines and procedures. A full list of exclusion criteria are 134 provided in the trial protocol. 135

If a patient met the above eligibility criteria, study personnel obtained written informed 136 consent. After obtaining informed consent a rapid antigen test for COVID-19 (Panbio ®, Abbott 137 laboratories) and a pregnancy test for women of childbearing age were performed. If the COVID-138 19 test was negative or if the pregnancy test was positive, the participant was not included in the 139 trial. After informed consent, study personnel collected the following data prior to randomization: 140 demographics, medical history concomitant medications, co-morbidities, exposure to Index Case 141 information, WHO clinical worsening scale, and the PROMIS Global Health Scale. 142

Participants were randomized using a centralized core randomization process handled by an 144 independent unblinded pharmacist who was not aware of any protocol-related procedures and 145 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.19.21262323 doi: medRxiv preprint contracted specifically for this process. Sites requested randomization by text message to the 146 pharmacist at the coordinating center. This maintained concealment of allocation. Patients were 147 randomly assigned using a block randomization procedure for each participating site, stratified by 148 age (< 50 years /≥ 50 years). The trial team, site staff and patients were blinded to treatment 149 allocation. The active drugs and the placebo pills were packaged in identically shaped bottles and 150 labeled with alphabet letters corresponding to the active arm or placebo arm. Only the third-party 151 pharmacist responsible for releasing the randomization was aware of which letter was associated 152 with which drug and/or placebo. As this is a multi-arm trial and all active interventions have a 153 matching inert placebo, the matching placebo represents the proportion of the control group for 154 the number of arms in the trial at any given time. 155

Our primary outcome is a composite that includes emergency room visits due to the clinical 157 Study personnel collected, via in person, telephone contact and social media applications 167 using video-teleconferencing, outcome data on days 1, 2, 3, 4, 5, 7, 10, 14, and 28. We collected 168 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.19.21262323 doi: medRxiv preprint outcome data irrespective of whether participants took study medication. In case of adverse events, 169 unscheduled visits (during the treatment period) outside of clinical care could occur at any time. All serious and non-serious adverse events were reported to study personnel as per local 182 regulatory requirements. Reportable adverse events included serious adverse events, adverse 183 events resulting in study medication discontinuation, and adverse events assessed as possibly 184 related to study medication. 185

All participants received usual standard care for COVID-19 provided by healthcare professionals 187 workers at public health facilities. Patients were randomized to fluvoxamine (Luvox ®, Abbott) at 188 a dose of 100 mg twice a day for 10 days or corresponding placebo starting right after 189 randomization (day 1). Research personnel provided participants a welcome video with 190 information on trial, study drug, adverse events and follow-up procedures. Clinicians providing 191 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. Baseline characteristics are reported as count (percent) or median and interquartile range (IQR)for 204 continuous variables. We applied a Bayesian framework for our primary outcome analysis and a 205 frequentist approach for all sensitivity analyses and secondary outcomes. Posterior efficacy of 206 fluvoxamine for the primary outcome is calculated using the beta-binomial model for event rates, 207 assuming informed priors based on the observational data for both placebo and fluvoxamine, for 208

both Intention-to-Treat (ITT), modified ITT (defined as receiving the study drug for at least 24 209 hours before an event) and Per-Protocol (PP) analyses (defined as taking >80% of possible doses). 210

Modified ITT was defined as receiving treatment for at least 24 hours before a primary outcome. 211

We accounted for any temporal changes in events rates by using only the concurrent randomised 212 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.19.21262323 doi: medRxiv preprint population. We assessed subgroup effects according to the preplanned statistical analysis plan. We 213 calculated the number needed to treat. 214 Secondary outcomes were assessed using a pre-specified frequentist approach. For viral 215 clearance we fitted a longitudinal, mixed-effect logistic regression model with a treatment and time 216 interaction term for binary patient outcomes (Covid-19 positive/negative) reported on day 3 and 7 217 from randomization, with subject random effect. We assessed time-to-event outcomes using Cox 218 proportional hazard models and binary outcomes using logistic regression. Per protocol analyses 219 were considered sensitivity analyses to assess the robustness of the results. All analyses were 220 performed using R version 4.0.3. Full details of the Statistical Analysis Plan (SAP) are appended. 221

A Data and Safety Monitoring Committee provided independent oversight for this trial. We 223 planned a 4 th interim analysis of the fluvoxamine arm with data collected up to August 2 nd , 2021. 224

The funders had no role in the study design, data collection, analysis, interpretation or writing, or 226 decision to submit for publication. The executive committee take responsibility for the integrity of 227 the data and the accuracy of the data analysis. The trial executive committee oversaw all aspects 228 of trial conduct, completeness, data accuracy and adherence of trial conduct to the protocol and 229 the committee vouch for the accuracy and completeness of the data and for fidelity to the protocol. 230

We screened 9020 potential participants for inclusion in this trial to date. The trial enrolled its first 233 participant on June 2, 2020 and enrolment into the fluvoxamine arm began on January 20, 2021. 234 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.19.21262323 doi: medRxiv preprint By August 6, 2021, 1,472 recruited participants were randomized to fluvoxamine (n= 739) or the 235 concurrent placebo (n=733), and 1,766 were randomized to other treatment arms (Figure 1 ). The 236 median age was 50 years (range 18-102) and 846 (57.5%) were women (Table 1) . Most 237 participants self-identified as mixed-race 1,403 (95.3%), 11 (0.7%) as white, 10 (0.7%) as black 238

or African American, the rest self-identified as unknown 48 (3.3%). As the trial is ongoing, herein 239

we provide descriptive summaries of only those randomized to fluvoxamine and its concurrent 240 control. With respect to covariates of age, BMI, and co-morbidities, the groups were generally 241 well balanced (Table 1 ). The mean number of days with symptoms prior to randomization was 4 242 days (Standard Deviation 1.76). All patients were identified at the end of the study for inclusion 243 in the analysis. probability that the event rate was lower in the fluvoxamine group compared to placebo was 99.4% 254 for the ITT population, and 99.6% for the modified ITT population (Figure 2A/B) . These posterior 255 efficacy numbers were higher than the pre-specified 97.6% threshold set for the fourth interim 256 analysis. In the fluvoxamine group 77 (10.4%) participants experienced a primary outcome event 257

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.19.21262323 doi: medRxiv preprint compared to 108 (14.7%) in the placebo group (Table 2) . Most events (88%) were hospitalizations. 258

The number needed to treat is 24. Per protocol analysis demonstrated a larger treatment effect 259 (0.34, 95% BCI, 0.20-0.54). 260

261 Table 3 presents findings from secondary outcome analyses. There were no significant differences 

In the prespecified subgroup analysis, we found no evidence of moderation of treatment effect for 272 fluvoxamine compared to placebo, for sub-groups of age, sex, days since symptom onset, or co-273 morbidities (Figure 3 and web-appendix eTable 1). 274

This is the first large randomized controlled trial to test the efficacy of fluvoxamine for acute 277 treatment of COVID-19. We found a clinically important absolute risk reduction of 4.3%, and 278 29% relative risk reduction, on the primary outcome of retention in an emergency setting for 279 COVID-19 disease observation or hospitalization, consequent on the administration of 280 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.19.21262323 doi: medRxiv preprint fluvoxamine for 10 days. This study is only the 2 nd study to demonstrate an important treatment 281 benefit for a repurposed drug in the early treatment population. 11 Our findings represent the latest 282 interim analysis of the trial resulting in the DSMC recommending stopping the active fluvoxamine 283 arm. The final analysis from the trial, wherein all patients have contributed 28 days of follow-up 284 data, will be made available 28 days after the last randomized patient has completed this period 285 The underlying mechanism of fluvoxamine for COVID-19 disease remains uncertain. Although 297 hypotheses include several potential mechanisms, 4 the main reason for the initial study of 298 fluvoxamine as a treatment of COVID-19 was its anti-inflammatory action through activation of 299 the σ-1 receptor (S1R). 12 S1R is an endoplasmic reticulum (ER) chaperone membrane protein 300 involved in many cellular functions, 13 including regulation of ER stress response/unfolded protein 301 response and regulation of cytokine production in response to inflammatory triggers. 14 In the 302 presence of fluvoxamine, S1R may prevent the ER stress sensor Inositol-Requiring Enzyme 1α 303 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.19.21262323 doi: medRxiv preprint (IRE1) from splicing and activating the mRNA of X-Box Protein 1 (XBP1), a key regulator of 304 cytokine production including IL-6, IL-8, IL-1β and IL-12. In a 2019 study by Rosen and 305 colleagues, fluvoxamine showed benefit in preclinical models of inflammation and sepsis through 306 this mechanism. 14 307

Another mechanism may be fluvoxamine's anti-platelet activity. 15 SSRIs can prevent loading of 308 serotonin into platelets and inhibit platelet activation, that may reduce the risk of thrombosis, and 309 these antiplatelet effects can be cardioprotective. In vitro and animal studies are needed to help 310 clarify the most likely mechanism(s). Biomarker studies included as part of future RCTs may also 311 help to clarify mechanisms. 312 313

Since the start of the COVID-19 pandemic, there have been more than 2800 RCTs registered on 315 clinicaltrials.gov. However, less than 300 have been reported and the vast majority of clinical trials 316 have been small and underpowered, with sample sizes less than 100. In many cases, these trials 317

have been unsuccessful at recruiting as the local epidemics occur in waves and sustainable 318 infrastructure to maintain staff or local interest for recruitment is lacking. The trials that provide 319 the clearest medical understanding tend to be the larger platform trials, such as SOLIDARITY, 16 320 RECOVERY, 17 PRINCIPLE, 11 and REMAP-CAP. 18 As a result, we actively collaborate with other 321 investigators running trials with overlapping interventions so that they can be aware of our study 322 decisions and determine whether they should influence their respective trials. 323

Major strengths include the rapid recruitment and enrolment of high-risk patients for the 324 development of severe COVID-19. Our recruitment strategy involves the engagement with the 325 local public health system, thus allowing recruitment that frequently exceeds twenty patients per 326 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.19.21262323 doi: medRxiv preprint day. We enrolled only participants with diagnosed COVID-19 and less than 7 days of symptom 327 onset using a commercially available COVID-19 AG rapid test (Panbio ®). The concordance of 328 COVID-19 positive tests with RT-PCR was evaluated on the group of participants with PCR 329 evaluations and found a concordance rate of > 99% on both tests collected at baseline. interventions, including some of those evaluated in this and our previous trials. Furthermore, there 347 is little understanding of who is at greatest risk of disease progression from this disease as some 348 patients with numerous risk factors do recover quickly while some others with less established risk 349 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.19.21262323 doi: medRxiv preprint factors may not. Our population had a higher rate of hospitalization events than observed in most 350 clinical trials, thus permitting inferences on treatment effects in this higher-risk population. Fluvoxamine is widely available but is not on the WHO Essential Medicines List, 22 whereas a 365 closely related SSRI fluoxetine is on the list. It is now of critical importance to determine whether 366 a class-effect exists and whether these drugs can be used interchangeably for COVID-19. The 367 recent important findings that inhaled budesonide increased time to recovery among a similar 368 population as our trial and had a trend towards decreased hospitalizations suggests this as an 369 alternative or additional intervention for outpatient care that should be evaluated. The PRINCIPLE 370 trial evaluated time to recovery using self-reported recovery up to 28 days after randomization to 371 budesonide. 11 Our trial differed as we evaluated improvement in the WHO categorization of 372 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.19.21262323 doi: medRxiv preprint disease disability up to days 14 and then 28 (web-appendix eFigure 2). Finally, our study was . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.19.21262323 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.19.21262323 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) LEGEND: + Self-identified as someone with mixed-race ancestry.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 23, 2021. ; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.19.21262323 doi: medRxiv preprint 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted August 23, 2021. ; https://doi.org/10.1101/2021.08.19.21262323 doi: medRxiv preprint

COVID-19 vaccination: returning to 416 WHO's Health For All

Accelerating Clinical Evaluation of Repurposed 418 Combination Therapies for COVID-19

Fluvoxamine alleviates ER stress via induction 420 of Sigma-1 receptor

Fluvoxamine: A Review of Its 422 Mechanism of Action and Its Role in COVID-19

Association between antidepressant use and 425 reduced risk of intubation or death in hospitalized patients with COVID-19: results from an 426 observational study

Fluvoxamine vs Placebo and Clinical 428 Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial

Systematic review of basket trials, umbrella trials, and 431 platform trials: a landscape analysis of master protocols

Master Protocols to Study Multiple Therapies, Multiple 433 Diseases, or Both

A multi-center, adaptive, randomized, platform 435 trial to evaluate the effect of repurposed medicines in outpatients with early coronavirus disease 436 2019 (COVID-19) and high-risk for complications: the TOGETHER master trial protocol

Effect of Early Treatment With 439

Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With 440 COVID-19: The TOGETHER Randomized Clinical Trial

Inhaled budesonide for COVID-19 in people at 442 high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, 443 open-label, adaptive platform trial

Repurposing Psychiatry During the COVID-19 Pandemic

Interaction of new antidepressants with sigma-1 receptor 447 chaperones and their potentiation of neurite outgrowth in PC12 cells

Modulation of the sigma-1 receptor-450 IRE1 pathway is beneficial in preclinical models of inflammation and sepsis

Effect of selective serotonin reuptake inhibitors on platelet 453 activation: can they prevent acute myocardial infarction?

Repurposed Antiviral Drugs for Covid-19 -456 Interim WHO Solidarity Trial Results

Tocilizumab in patients admitted to hospital 458 with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, 459 platform trial

Effect of Hydrocortisone on Mortality and Organ 461 Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid 462 Domain Randomized Clinical Trial

Minimum manufacturing costs, national prices and 464 estimated global availability of new repurposed therapies for COVID-19. medRxiv 2021

REGN-COV2, a Neutralizing Antibody 468 Cocktail, in Outpatients with Covid-19

World Health Organization model list of essential medicines: 21st list 470 2019: World Health Organization